These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 23821689)

  • 41. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
    Miller MP; Trujillo TC; Nordenholz KE
    Am J Emerg Med; 2014 Apr; 32(4):375-82. PubMed ID: 24512886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The new Anticoagulants - Relevant Facts for the GP].
    Asmis LM
    Praxis (Bern 1994); 2011 Aug; 100(16):971-6. PubMed ID: 21833915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies for urgent reversal of target-specific oral anticoagulants.
    Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
    Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM; Garcia DA; Crowther MA
    Blood; 2014 Feb; 123(8):1152-8. PubMed ID: 24385535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
    Lazo-Langner A; Lang ES; Douketis J
    Crit Care; 2013 Jun; 17(3):230. PubMed ID: 23806169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract]   [Full Text] [Related]  

  • 49. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
    Desai J; Kolb JM; Weitz JI; Aisenberg J
    Thromb Haemost; 2013 Aug; 110(2):205-12. PubMed ID: 23702623
    [No Abstract]   [Full Text] [Related]  

  • 50. Managing bleeding in anticoagulated patients in the emergency care setting.
    Pollack CV
    J Emerg Med; 2013 Sep; 45(3):467-77. PubMed ID: 23786779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):34-40. PubMed ID: 24463062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [From heparin to apixaban: anticoagulants cut both ways?].
    Hartung K; Meyer F; Bock F; Isermann B
    Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Steurer J
    Praxis (Bern 1994); 2014 Aug; 103(17):1032. PubMed ID: 25146949
    [No Abstract]   [Full Text] [Related]  

  • 55. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
    Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal risk stratification with the new oral anticoagulants (July 2013).
    Pazmiño P
    Cleve Clin J Med; 2013 Nov; 80(11):733-4. PubMed ID: 24186892
    [No Abstract]   [Full Text] [Related]  

  • 57. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recommendations on use of direct oral anticoagulants in the perioperative period].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():46-50. PubMed ID: 23498073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pharmacologic heterogeneity of new anticoagulants].
    Samamaa MM; Conard J; Flaujac C; Combe S; Horellou MH
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S10-5. PubMed ID: 22177763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.